Crucell, DSM Biologics announce PER.C6 licensing agreement with UCB

By E. Janene Geiss

Philadelphia, March 14 - Crucell NV and allied contract manufacturer DSM Biologics announced Tuesday that they have signed a PER.C6 research license agreement with global biopharmaceutical leader UCB SA.

This agreement allows UCB to evaluate the PER.C6 cell line for research and manufacturing of monoclonal antibodies. Financial details were not disclosed, according to a company news release.

Crucell is a biotechnology company based in Leiden, The Netherlands, and focused on research, development, production and worldwide marketing of vaccines and antibodies that combat infectious diseases.

DSM Biologics, a business unit of DSM Pharmaceutical Products in Groningen, The Netherlands, is a provider of manufacturing technology and services to the biopharmaceutical industry.

DSM Biologics has co-exclusive rights, along with Crucell, to license the high-producing PER.C6 human cell line as a production platform for recombinant proteins and monoclonal antibodies.

UCB is a Brussels, Belgium, biopharmaceutical company specializing in central nervous system disorders, inflammatory diseases and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.